On June 10, 2024, Sterling O. James, the Chief Financial Officer of bluebird bio, Inc., filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as mandated by Section 16(a) of the Securities Exchange Act of 1934. The filing, which is a standard requirement for officers, directors, and certain beneficial owners of public companies, indicates that Sterling O. James does not beneficially own any securities in the company. The form was filed individually by James and was signed by Sydney Gaylin, Attorney-in-Fact, on June 13, 2024. This filing is part of the regulatory requirements that ensure transparency of ownership by key executives and is closely monitored by investors for any changes in ownership that might influence the company's stock performance.

On June 10, 2024, Sterling O. James, the Chief Financial Officer of bluebird bio, Inc., filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as mandated by Section 16(a) of the Securities Exchange Act of 1934. The filing, which is a standard requirement for officers, directors, and certain beneficial owners of public companies, indicates that Sterling O. James does not beneficially own any securities in the company. The form was filed individually by James and was signed by Sydney Gaylin, Attorney-in-Fact, on June 13, 2024. This filing is part of the regulatory requirements that ensure transparency of ownership by key executives and is closely monitored by investors for any changes in ownership that might influence the company's stock performance.